ArticleBreast cancer research : BCR2005
Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families.
Article in Breast cancer research : BCR, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Tumor-infiltrating lymphocytes are the key determinants of pathological features associated with pathogenicFrontiers in medicine · 2025Article
- PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants.NPJ breast cancer · 2023Article
- What Is Known about Breast Cancer in Young Women?Cancers · 2023Review
- Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.Journal of human genetics · 2021Article
- Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants.NPJ breast cancer · 2021Article
- Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients.Journal of pathology and translational medicine · 2020Review
- Association of Genomic Domains inCancer research · 2020Article
- Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.BMC cancer · 2019Article
- BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.Molecular genetics & genomic medicine · 2019Article
- Clinical and pathologic characteristics of breast cancer patients carrying the c.3481_3491del11 mutation.Familial cancer · 2019Article
- Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients withJournal of breast cancer · 2018Article
- Multicenter cross-sectional screening of theOncology letters · 2018Article
- Molecular Diagnostics in Clinical Oncology.Frontiers in molecular biosciences · 2018Review
- FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.Breast cancer research and treatment · 2017Article
- The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation.Oncotarget · 2017Article
- FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.International journal of cancer · 2016Article
- Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.Familial cancer · 2016Review
- DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3.Journal of translational medicine · 2015Article
- Article
- Cooperation of DLC1 and CDK6 affects breast cancer clinical outcome.G3 (Bethesda, Md.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHistopathological features of BRCA1 and BRCA2 tumours have previously been characterised and compared with unselected breast tumours; however, familial non-BRCA1/2 tumours are less well known. The aim of this study was to characterise familial non-BRCA1/2 tumours and to evaluate routine immunohistochemical and pathological markers that could help us to further distinguish families carrying BRCA1/2 mutations from other breast cancer families.
methodsBreast cancer tissue specimens (n = 262) from 25 BRCA1, 20 BRCA2 and 74 non-BRCA1/2 families were studied on a tumour tissue microarray. Immunohistochemical staining of oestrogen receptor (ER), progesterone receptor (PgR) and p53 as well as the histology and grade of these three groups were compared with each other and with the respective information on 862 unselected control patients from the archives of the Pathology Department of Helsinki University Central Hospital. Immunohistochemical staining of erbB2 was also performed among familial cases.
resultsBRCA1-associated cancers were diagnosed younger and were more ER-negative and PgR-negative, p53-positive and of higher grade than the other tumours. However, in multivariate analysis the independent factors compared with non-BRCA1/2 tumours were age, grade and PgR negativity. BRCA2 cases did not have such distinctive features compared with non-BRCA1/2 tumours or with unselected control tumours. Familial cases without BRCA1/2 mutations had tumours of lower grade than the other groups.
conclusionsBRCA1 families differed from mutation-negative families by age, grade and PgR status, whereas ER status was not an independent marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.